TORC1 inhibition enhances immune function and reduces infections in the elderly.
Level 2 - randomized trial
Phase 2a randomized placebo-controlled clinical trial
PubMed 29997249 · doi:10.1126/scitranslmed.aaq1564
What was done
A phase 2a randomized, placebo-controlled clinical trial evaluated whether 6 weeks of low-dose mTOR inhibitor therapy (a combination of catalytic inhibitor BEZ235 and allosteric inhibitor RAD001 targeting TORC1) could enhance immune response and reduce infections in 264 elderly participants followed for 1 year after study drug initiation.
What was found
Low-dose selective TORC1 inhibition was safe and significantly reduced the rate of reported infections over the 1-year follow-up compared to placebo (P = 0.001). The intervention also led to up-regulation of antiviral gene expression and improved response to influenza vaccination. Specific baseline rates, relative risks, and numerical vaccine titers were not provided in the abstract.
Why it matters
This trial suggests that short-term pharmacological targeting of aging biology (TORC1 pathway) can clinically enhance immune function and reduce infection burden in older adults.
Limits
The abstract lacks exact event counts, absolute effect sizes, confidence intervals, and safety event numbers. Infections appear to be subject-reported, and the study was a phase 2a trial requiring validation in larger confirmatory phase 3 studies.
Cited by
- supports A clinical trial in elderly individuals found that intermittent dosing of rapamycin improved immune function and vaccine response, whereas continuous dosing did not.